Across TCGA pan-cancer cohorts, SELENOT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SELENOT data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SELENOT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SELENOT expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where SELENOT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.799	0.547	.003	45	view →
CCRCC	OS	Median	All	0.613	1.000	.004	26	view →
LUAD	DFS	Quartile	II,III,IV	1.000	0.550	.034	11	view →
PDAC	DFS	Median	III,IV	0.266	0.827	.022	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SELENOT tumor-vs-normal RNA expression · all SELENOT data types